Eradication Treatment of Helicobacter pylori Infection Based on Molecular Pathologic Antibiotic Resistance

References

• Smith SM, O’Morain C, McNamara D. Helicobacter pylori resistance to current therapies. Curr Opin Gastroenterol. 2019;35(1):6–13. doi:10.1097/MOG.000000000000049730489412
   PubMed Web of Science ®Google Scholar
• Quaglia NC, Dambrosio A. Helicobacter pylori: a foodborne pathogen? World J Gastroenterol. 2018;24(31):3472–3487. doi:10.3748/wjg.v24.i31.347230131654
   PubMed Web of Science ®Google Scholar
• Sjomina O, Pavlova J, Niv Y, Leja M. Epidemiology of Helicobacter pylori infection. Helicobacter. 2018;23(Suppl 1):e12514. doi:10.1111/hel.2018.23.issue-S130203587
   PubMed Web of Science ®Google Scholar
• Mansour-Ghanaei F, Pedarpour Z, Shafaghi A, Joukar F. Clarithromycin versus gemifloxacin in quadruple therapeutic regimens for helicobacter pylori infection eradication. Middle East J Dig Dis. 2017;9(2):100–106. doi:10.15171/mejdd.2017.5828638586
   PubMedGoogle Scholar
• Malfertheiner P, Megraud F, O’Morain CA, et al. Management of Helicobacter pylori infection-the Maastricht V/Florence consensus report. Gut. 2017;66(1):6–30.27707777
   PubMed Web of Science ®Google Scholar
• Sugano K, Tack J, Kuipers EJ, et al. Kyoto global consensus report on Helicobacter pylori gastritis. Gut. 2015;64(9):1353–1367. doi:10.1136/gutjnl-2015-30925226187502
   PubMed Web of Science ®Google Scholar
• Fallone CA, Chiba N, van Zanten SV, et al. The toronto consensus for the treatment of Helicobacter pylori infection in adults. Gastroenterology. 2016;151(1):51–69 e14. doi:10.1053/j.gastro.2016.04.00627102658
   PubMed Web of Science ®Google Scholar
• Liu WZ, Xie Y, Lu H, et al. Fifth Chinese national consensus report on the management of Helicobacter pylori infection. Helicobacter. 2018;23(2):e12475. doi:10.1111/hel.2018.23.issue-229512258
   PubMed Web of Science ®Google Scholar
• Zhang YX, Zhou LY, Song ZQ, et al. Primary antibiotic resistance of Helicobacter pylori strains isolated from patients with dyspeptic symptoms in Beijing: a prospective serial study. World J Gastroenterol. 2015;21(9):2786–2792. doi:10.3748/wjg.v21.i9.278625759550
   PubMed Web of Science ®Google Scholar
• Zhou L, Zhang J, Song Z, et al. Tailored versus triple plus bismuth or concomitant therapy as initial helicobacter pylori treatment: a randomized trial. Helicobacter. 2016;21(2):91–99. doi:10.1111/hel.2016.21.issue-226104022
   PubMed Web of Science ®Google Scholar
• Xie C, Lu NH. Review: clinical management of Helicobacter pylori infection in China. Helicobacter. 2015;20(1):1–10. doi:10.1111/hel.12178
   PubMed Web of Science ®Google Scholar
• Cosme A, Lizasoan J, Montes M, et al. Antimicrobial susceptibility-guided therapy versus empirical concomitant therapy for eradication of Helicobacter pylori in a region with high rate of clarithromycin resistance. Helicobacter. 2016;21(1):29–34. doi:10.1111/hel.2016.21.issue-125982426
   PubMed Web of Science ®Google Scholar
• Beckman E, Saracino I, Fiorini G, et al. A novel stool PCR test for Helicobacter pylori may predict Clarithromycin resistance and eradication of infection at a high rate. J Clin Microbiol. 2017;55(8):2400–2405. doi:10.1128/JCM.00506-1728515219
   PubMed Web of Science ®Google Scholar
• Pourakbari B, Mahmoudi S, Parhiz J, et al. High frequency of metronidazole and clarithromycin-resistant Helicobacter pylori in formalin-fixed, paraffin-embedded gastric biopsies. Br J Biomed Sci. 2018;75(2):61–65. doi:10.1080/09674845.2017.139146629452048
   PubMed Web of Science ®Google Scholar
• de Francesco V, Margiotta M, Zullo A, et al. Primary clarithromycin resistance in Italy assessed on Helicobacter pylori DNA sequences by TaqMan real-time polymerase chain reaction. Aliment Pharmacol Ther. 2006;23(3):429–435. doi:10.1111/apt.2006.23.issue-316423002
   PubMed Web of Science ®Google Scholar
• Hanafiah A, Binmaeil H, Raja Ali RA, Mohamed Rose I, Lopes BS. Molecular characterization and prevalence of antibiotic resistance in Helicobacter pylori isolates in Kuala Lumpur, Malaysia. Infect Drug Resist. 2019;12:3051–3061. doi:10.2147/IDR.S21906931632095
   PubMed Web of Science ®Google Scholar
• Kouitcheu Mabeku LB, Eyoum Bille B, Tepap Zemnou C, Tali Nguefack LD, Leundji H. Broad spectrum resistance in Helicobacter pylori isolated from gastric biopsies of patients with dyspepsia in Cameroon and efflux-mediated multiresistance detection in MDR isolates. BMC Infect Dis. 2019;19(1):880. doi:10.1186/s12879-019-4536-831640588
   PubMed Web of Science ®Google Scholar
• Lee JY, Kim N, Nam RH, et al. Primary and secondary antibiotic resistance of Helicobacter pylori in Korea from 2003 to 2018. Helicobacter. 2019;e12660.31507036
   PubMed Web of Science ®Google Scholar
• Patel SK, Pratap CB, Jain AK, Gulati AK, Nath G. Diagnosis of Helicobacter pylori: what should be the gold standard? World J Gastroenterol. 2014;20(36):12847–12859. doi:10.3748/wjg.v20.i36.1284725278682
   PubMed Web of Science ®Google Scholar
• Krashias G, Bashiardes S, Potamitou A, Potamitis GS, Christodoulou C. Prevalence of Helicobacter pylori cagA and vacA genes in Cypriot patients. J Infect Dev Ctries. 2013;7(9):642–650. doi:10.3855/jidc.292324042099
   PubMed Web of Science ®Google Scholar
• Lin YA, Wang H, Gu ZJ, et al. Effect of CYP2C19 gene polymorphisms on proton pump inhibitor, amoxicillin, and levofloxacin triple therapy for eradication of Helicobacter pylori. Med Sci Monit. 2017;23:2701–2707. doi:10.12659/MSM.90151428577017
   PubMed Web of Science ®Google Scholar
• Peng X, Song Z, He L, et al. Gastric juice-based real-time PCR for tailored Helicobacter pylori treatment: a practical approach. Int J Med Sci. 2017;14(6):595–601. doi:10.7150/ijms.1899628638276
   PubMed Web of Science ®Google Scholar
• Afonina I, Zivarts M, Kutyavin I, et al. Efficient priming of PCR with short oligonucleotides conjugated to a minor groove binder. Nucleic Acids Res. 1997;25(13):2657–2660. doi:10.1093/nar/25.13.26579185578
   PubMed Web of Science ®Google Scholar
• Kim BJ, Kim JG. Substitutions in penicillin-binding protein 1 in amoxicillin-resistant Helicobacter pylori strains isolated from Korean patients. Gut Liver. 2013;7(6):655–660. doi:10.5009/gnl.2013.7.6.65524312705
   PubMed Web of Science ®Google Scholar
• Gonzalez-Hormazabal P, Musleh M, Escandar S, et al. Prevalence of clarithromycin resistance in Helicobacter pylori in Santiago, Chile, estimated by real-time PCR directly from gastric mucosa. BMC Gastroenterol. 2018;18(1):91. doi:10.1186/s12876-018-0820-029925321
   PubMed Web of Science ®Google Scholar
• Lee SM, Kim N, Kwon YH, et al. rdxA, frxA, and efflux pump in metronidazole-resistant Helicobacter pylori: their relation to clinical outcomes. J Gastroenterol Hepatol. 2018;33(3):681–688. doi:10.1111/jgh.1390628748532
   PubMed Web of Science ®Google Scholar
• Rimbara E, Noguchi N, Kawai T, Sasatsu M. Fluoroquinolone resistance in Helicobacter pylori: role of mutations at position 87 and 91 of GyrA on the level of resistance and identification of a resistance conferring mutation in GyrB. Helicobacter. 2012;17(1):36–42. doi:10.1111/hel.2011.17.issue-1
   Web of Science ®Google Scholar
• Wu JY, Kim JJ, Reddy R, et al. Tetracycline-resistant clinical Helicobacter pylori isolates with and without mutations in 16S rRNA-encoding genes. Antimicrob Agents Chemother. 2005;49(2):578–583. doi:10.1128/AAC.49.2.578-583.200515673736
   PubMed Web of Science ®Google Scholar
• Zhang YW, Hu WL, Cai Y, et al. Outcomes of furazolidone- and amoxicillin-based quadruple therapy for Helicobacter pylori infection and predictors of failed eradication. World J Gastroenterol. 2018;24(40):4596–4605. doi:10.3748/wjg.v24.i40.459630386109
   PubMed Web of Science ®Google Scholar
• Xie Y, Zhang Z, Hong J, et al. Furazolidone-containing triple and quadruple eradication therapy for initial treatment for Helicobacter pylori infection: a multicenter randomized controlled trial in China. Helicobacter. 2018;23(5):e12496. doi:10.1111/hel.2018.23.issue-530033619
   PubMed Web of Science ®Google Scholar
• Djennane-Hadibi F, Bachtarzi M, Layaida K, et al. High-level primary clarithromycin resistance of Helicobacter pylori in Algiers, Algeria: a prospective multicenter molecular study. Microb Drug Resist. 2016;22(3):223–226. doi:10.1089/mdr.2015.020926554340
   PubMed Web of Science ®Google Scholar
• Hakemi Vala M, Eyvazi S, Goudarzi H, Sarie HR, Gholami M. Evaluation of clarithromycin resistance among Iranian Helicobacter pylori isolates by E-test and real-time polymerase chain reaction methods. Jundishapur J Microbiol. 2016;9(5):e29839. doi:10.5812/jjm27540451
   PubMed Web of Science ®Google Scholar
• Dzierzanowska-Fangrat K, Rozynek E, Jozwiak P, et al. Primary resistance to clarithromycin in clinical strains of Helicobacter pylori isolated from children in Poland. Int J Antimicrob Agents. 2001;18(4):387–390. doi:10.1016/S0924-8579(01)00421-611691574
   PubMed Web of Science ®Google Scholar
• Agudo S, Perez-Perez G, Alarcon T, Lopez-Brea M. High prevalence of clarithromycin-resistant Helicobacter pylori strains and risk factors associated with resistance in Madrid, Spain. J Clin Microbiol. 2010;48(10):3703–3707. doi:10.1128/JCM.00144-1020668128
   PubMed Web of Science ®Google Scholar
• Chang YW, Ko WJ, Oh CH, et al. Clarithromycin resistance and female gender affect Helicobacter pylori eradication failure in chronic gastritis. Korean J Intern Med. 2019;34(5):1022–1029. doi:10.3904/kjim.2018.05429898576
   PubMed Web of Science ®Google Scholar
• Kim SE, Park MI, Park SJ, et al. Trends in Helicobacter pylori eradication rates by first-line triple therapy and related factors in eradication therapy. Korean J Intern Med. 2015;30(6):801–807. doi:10.3904/kjim.2015.30.6.80126552455
   PubMed Web of Science ®Google Scholar
• Park CG, Kim S, Lee EJ, Jeon HS, Han S. Clinical relevance of point mutations in the 23S rRNA gene in Helicobacter pylori eradication: a prospective, observational study. Medicine (Baltimore). 2018;97(33):e11835. doi:10.1097/MD.000000000001183530113472
   PubMed Web of Science ®Google Scholar
• Chen Q, Zhang W, Fu Q, et al. Rescue therapy for helicobacter pylori eradication: a randomized non-inferiority trial of amoxicillin or tetracycline in bismuth quadruple therapy. Am J Gastroenterol. 2016;111(12):1736–1742. doi:10.1038/ajg.2016.44327670603
   PubMed Web of Science ®Google Scholar
• Ashida K, Honda Y, Sanada K, Takemura Y, Sakamoto S. The safety and effectiveness of vonoprazan-based Helicobacter pylori eradication therapy; a prospective post-marketing surveillance. Expert Opin Drug Saf. 2019;18:1–7.30582380
   PubMed Web of Science ®Google Scholar
• Mansour-Ghanaei F, Samadi A, Joukar F, et al. Efficacy and tolerability of fourteen-day sequential quadruple regimen: pantoprazole, bismuth, amoxicillin, metronidazole and or furazolidone as first-line therapy for eradication of Helicobacter pylori: a randomized, double-blind clinical trial. EXCLI J. 2019;18:644–652. doi:10.17179/excli2019-161331611747
   PubMed Web of Science ®Google Scholar
• Gebeyehu E, Nigatu D, Engidawork E. Helicobacter pylori eradication rate of standard triple therapy and factors affecting eradication rate at Bahir Dar city administration, Northwest Ethiopia: a prospective follow up study. PLoS One. 2019;14(6):e0217645. doi:10.1371/journal.pone.021764531163069
   PubMed Web of Science ®Google Scholar
• Silva GM, Silva HM, Nascimento J, et al. Helicobacter pylori antimicrobial resistance in a pediatric population. Helicobacter. 2018;23(5):e12528. doi:10.1111/hel.1252830091503
   PubMed Web of Science ®Google Scholar
• Dekhnich N, Ivanchik N, Kozlov R, et al. Dynamics of antimicrobial resistance of Helicobacter pylori isolates in the Smolensk region of Russian Federation. Helicobacter. 2018;23(6):e12545. doi:10.1111/hel.2018.23.issue-630324756
   PubMed Web of Science ®Google Scholar